What type of study is this?

This research is Trending!

September 5, 2025New England Journal of Medicine

Beta-Blockers after Myocardial Infarction in Patients without Heart Failure

View Full Paper

Ask AI

Bookmark

Authors

JMJohn MunkhaugenPreventive Cardiology AKAnna Meta Dyrvig KristensenFrederiksberg Hospital JJJarle JortveitGeneral Cardiology

Discussion

Member takes

Implication

Randomized trial demonstrates beta-blocker therapy reduces death and cardiovascular events in myocardial infarction patients, indicating effectiveness post-MI.

Key Points

Beta-blocker therapy reduced the risk of death from any cause or major adverse cardiovascular events by 15% compared to no therapy.
In the beta-blocker group, 14.2% experienced primary endpoint events, versus 16.3% in the no-beta-blocker group after 3.5 years.
Conducted as an open-label, randomized trial with blinded endpoint evaluation in Denmark and Norway, research involved 5574 patients.
This research may enable better strategies for post-myocardial infarction care and encourage further studies into β-blockade therapy.

Cite This Study

Munkhaugen et al. (2025) studied this question.

synapsesocial.com/papers/68bb3a2b2b87ece8dc954847 https://doi.org/10.1056/nejmoa2505985

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates beta-blocker therapy reduces death and cardiovascular events in myocardial infarction patients, indicating effectiveness post-MI.

Beta-Blockers after Myocardial Infarction in Patients without Heart Failure

Discussion

Member takes

Implication

Key Points

Cite This Study

Beta-Blockers after Myocardial Infarction in Patients without Heart Failure

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider